Cephalexin
- Generic Name
- Cephalexin
- Brand Names
- Keflex
- Drug Type
- Small Molecule
- Chemical Formula
- C16H17N3O4S
- CAS Number
- 15686-71-2
- Unique Ingredient Identifier
- 5SFF1W6677
- Background
Cephalexin is the first of the first generation cephalosporins. This antibiotic contains a beta lactam and a dihydrothiazide. Cephalexin is used to treat a number of susceptible bacterial infections through inhibition of cell wall synthesis. Cephalexin was approved by the FDA on 4 January 1971.
- Indication
Cephalexin is indicated for the treatment of certain infections caused by susceptible bacteria. These infections include respiratory tract infections, otitis media, skin and skin structure infections, bone infections, and genitourinary tract infections.
- Associated Conditions
- Bone Infection, Genitourinary tract infection, Otitis Media (OM), Respiratory Tract Infections (RTI), Skin and skin structure infections, Acute Prostatitis
- Associated Therapies
- -
Patient-Directed Antimicrobial Duration in Acute Uncomplicated Pyelonephritis
- Conditions
- Interventions
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Brett A Faine
- Target Recruit Count
- 40
- Registration Number
- NCT06127160
- Locations
- 🇺🇸
Olive View - UCLA Medical Center, Sylmar, California, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Antibiotic Prophylaxis in Pediatric Open Fractures
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- St. Louis University
- Target Recruit Count
- 800
- Registration Number
- NCT06055712
- Locations
- 🇺🇸
Saint Louis University, Saint Louis, Missouri, United States
High-dose Cephalexin for Cellulitis (HI-DOCC)
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 446
- Registration Number
- NCT05852262
- Locations
- 🇨🇦
Foothills Medical Centre, Calgary, Alberta, Canada
🇨🇦Hôpital du Sacré-Cœur de Montréal, Montréal, Quebec, Canada
🇨🇦Kingston Health Sciences Centre, Kingston, Ontario, Canada
The BLAST- 1 Trial - Cephalexin+Amoxicillin-clavulanate for Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- Western Sydney Local Health District
- Target Recruit Count
- 30
- Registration Number
- NCT05664568
- Locations
- 🇦🇺
Royal Prince Alfred Hospital, Sydney, Australia
🇦🇺Western Sydney Health District, Sydney, Australia
🇦🇺Blacktown Hospital, Sydney, Australia
Role of Prophylactic Postoperative Antibiotics in HoLEP
- First Posted Date
- 2022-03-10
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Baylor Research Institute
- Target Recruit Count
- 100
- Registration Number
- NCT05274672
- Locations
- 🇺🇸
Einstein Healthcare network, Philadelphia, Pennsylvania, United States
🇺🇸Baylor Scott and White, Temple, Texas, United States
Microbiome and Association With Implant Infections
- Conditions
- Interventions
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 200
- Registration Number
- NCT05020574
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Oral Amoxicillin and Cephalexin PK/PD in Neonates
- First Posted Date
- 2021-06-08
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 60
- Registration Number
- NCT04916951
- Locations
- 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
Postoperative Antibiotics Following Primary and Secondary Breast Augmentation
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2022-09-14
- Lead Sponsor
- University of California, Los Angeles
- Registration Number
- NCT04834310
Utility of Single-dose Oral Antibiotic Prophylaxis in Prevention of Surgical Site Infection in Dermatologic Surgery
- Conditions
- Interventions
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Carilion Clinic
- Target Recruit Count
- 1600
- Registration Number
- NCT04580472
- Locations
- 🇺🇸
Carilion Clinic, Roanoke, Virginia, United States
Antibiotic Treatment Of Staphylococcus Aureus In Stable People With CF
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2022-01-14
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 86
- Registration Number
- NCT04553419
- Locations
- 🇨🇦
BC Children's Hospital, Vancouver, British Columbia, Canada
🇨🇦The Hospital For Sick Children, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.